Showing 3711-3720 of 6035 results for "".
- EyePoint Pharmaceuticals Names Jay S. Duker, MD, Chief Strategic Scientific Officerhttps://modernod.com/news/eyepoint-pharmaceuticals-names-jay-s-duker-md-chief-strategic-scientific-officer/2478005/EyePoint Pharmaceuticals announced the appointment of Jay S. Duker, MD, as Chief Strategic Scientific Officer. In this newly created role, Dr. Duker will lead the strategic advancement of our research and development efforts, beginning with our lead development candidate EYP-1901 for wet age-rela
- OCT Angiography Demonstrates Retinal Involvement in Amblyopiahttps://modernod.com/news/oct-angiography-demonstrates-retinal-involvement-in-amblyopia/2478003/Optical coherence tomography angiography (OCT-A) could play a role in diagnosing and understanding the pathogenesis of amblyopia, researchers in Hong Kong report, according to a Reuters report. “Our study, utilizing high-reso
- Numab Therapeutics and Boehringer Ingelheim Enter into Collaboration to Develop Multi-Specific Antibody Therapeutics for Cancer and Retinal Diseaseshttps://modernod.com/news/numab-therapeutics-and-boehringer-ingelheim-enter-into-collaboration-to-develop-multi-specific-antibody-therapeutics-for-cancer-and-retinal-diseases/2478000/Boehringer Ingelheim and Numab Therapeutics announced that they have entered into a research collaboration and worldwide licensing agreement. It will start with two projects aiming at novel therapies for difficult-to-treat lung and gastrointestinal (GI) cancers and patients with geographic
- The FDA Does Not Approve Allergan’s Wet AMD Drug Candidate Abicipar Pegolhttps://modernod.com/news/allergan-and-molecular-partners-receive-complete-response-letter-from-fda-on-biologics-license-application-for-abicipar-pegol/2477937/Citing an unfavorable benefit-risk ratio, the FDA rejected Allergan and co-developer Molecular Partners’ wet AMD drug candidate Abicipar pegol. The FDA issued a complete response letter to the biologics license application (BLA) for Abicipar pegol, a novel, investigational DARPin the
- Saunders Finds Life After Allergan on Board at Newly IPO’ed BridgeBiohttps://modernod.com/news/saunders-finds-life-after-allergan-on-board-at-newly-ipoed-bridgebio/2477933/Less than 2 months after Allergan was officially taken in by AbbVie, its last helmsman, Brent Saunders, has landed on the board of a young biotech that recently pulled off a large IPO, according to a FiercePharma
- AsclepiX Therapeutics Announces $35 Million Series A Financinghttps://modernod.com/news/asclepix-therapeutics-announces-35-million-series-a-financing/2477929/AsclepiX Therapeutics announced that it has closed a $35 million Series A financing to fund phase 1/2a clinical trials of AXT107, the company’s lead investigational drug, for the treatment of diabetic macular edema (DME), wet age-related macular degeneration (AMD) and macular edema secondary to r
- Lineage Cell Therapeutics Reinitiates Patient Enrollment in Clinical Study of OpRegen for the Treatment of Dry AMD With GAhttps://modernod.com/news/lineage-cell-therapeutics-reinitiates-patient-enrollment-in-clinical-study-of-opregen-for-the-treatment-of-dry-amd-with-geographic-atrophy/2477911/Lineage Cell Therapeutics announced that it has restarted patient enrollment in a phase 1/2a clinical study of its lead product candidate, OpRegen, a retinal pigment epithelium (RPE) cell transplant therapy currently in development for the treatment of dry age-related macular degeneration (AMD),
- FAH Demands More Time For Providers to Repay Advance Medicare Payments Due Soonhttps://modernod.com/news/fah-demands-more-time-for-providers-to-repay-advance-medicare-payments-due-soon/2477909/The Federation of American Hospitals is imploring Medicare to give providers more time to repay advanced Medicare loans sent out to help providers facing a financial crisis from COVID-19, according to a FierceHealthcare
- Five Coronavirus Treatments In Developmenthttps://modernod.com/news/five-coronavirus-treatments-in-development/2479524/Right now, there is only one drug shown by rigorous scientific testing to be helpful for treating COVID-19. That drug is the antiviral medication called remdesivir, made by Gilead Sciences. But remdesivir’s proven benefits
- Study: Vision Loss Influences Perception of Soundhttps://modernod.com/news/study-vision-loss-influences-perception-of-sound/2477884/People with severe vision loss can less accurately judge the distance of nearby sounds, potentially putting them more at risk of injury, according to new research published in the journal Scientific Reports. Researchers from Anglia Ruskin University’s Vision and Eye Research Insti